相似文献
1
De Novo Oligometastatic Breast Cancer.
J Clin Oncol. 2023 Dec 1;41(34):5237-5241. doi: 10.1200/JCO.23.00911. Epub 2023 Aug 22.
2
Clinicopathologic factors associated with de novo metastatic breast cancer.
Pathol Res Pract. 2016 Dec;212(12):1167-1173. doi: 10.1016/j.prp.2016.09.007. Epub 2016 Sep 22.
3
Oligometastatic breast cancer: Are we there yet?
Int J Cancer. 2021 Oct 15;149(8):1520-1528. doi: 10.1002/ijc.33693. Epub 2021 Jun 8.
4
The oligometastatic state in breast cancer: hypothesis or reality.
Breast. 2005 Apr;14(2):87-93. doi: 10.1016/j.breast.2004.10.003.
5
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Br J Cancer. 2015 Apr 28;112(9):1445-51. doi: 10.1038/bjc.2015.127. Epub 2015 Apr 16.
6
[Treatment of primary disease with irradiation in case of de novo metastatic breast cancer].
Cancer Radiother. 2020 Oct;24(6-7):567-575. doi: 10.1016/j.canrad.2020.06.008. Epub 2020 Aug 16.
7
Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer.
Cancer Med. 2018 Apr;7(4):1183-1193. doi: 10.1002/cam4.1322. Epub 2018 Feb 26.
8
Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.
Cancer. 2024 Nov 15;130(22):3815-3825. doi: 10.1002/cncr.35466. Epub 2024 Jul 1.
9
Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E-RADIatE OligoCare cohort.
Radiother Oncol. 2024 Oct;199:110466. doi: 10.1016/j.radonc.2024.110466. Epub 2024 Jul 31.
10
The Difference in Prognostic Outcomes Between Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer.
In Vivo. 2018 Mar-Apr;32(2):353-358. doi: 10.21873/invivo.11245.
引用本文的文献
1
Surgeon Attitudes on the Management of de novo Oligometastatic Breast Cancer.
Ann Surg Oncol. 2025 Aug 6. doi: 10.1245/s10434-025-17912-7.
2
Breast Reconstruction in De Novo Metastatic Breast Cancer: A Systematic Review.
Plast Reconstr Surg Glob Open. 2025 Jun 2;13(6):e6810. doi: 10.1097/GOX.0000000000006810. eCollection 2025 Jun.
3
Survival outcomes and optimal candidates for primary tumor resection in head and neck squamous cell carcinoma with distant metastasis at initial diagnosis.
Eur Arch Otorhinolaryngol. 2025 Mar 7. doi: 10.1007/s00405-025-09305-z.
4
Accumulation of CD56 CD16 Natural Killer Cells in Response to Preoperative Chemotherapy for Breast Cancer.
World J Oncol. 2024 Aug;15(4):682-694. doi: 10.14740/wjon1885. Epub 2024 Jul 5.
5
The EANM-SNMMI guideline on the role of [18F]FDG-PET/CT in breast cancer: Important milestones and perspectives for the future.
Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2695-2700. doi: 10.1007/s00259-024-06758-y.
本文引用的文献
1
Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look?
J Clin Oncol. 2023 Aug 10;41(23):3891-3894. doi: 10.1200/JCO.23.00977. Epub 2023 Jun 22.
2
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
Nat Cancer. 2023 Jan;4(1):128-147. doi: 10.1038/s43018-022-00491-x. Epub 2022 Dec 30.
3
Oligometastases: Emerging Evidence.
J Clin Oncol. 2022 Dec 20;40(36):4250-4260. doi: 10.1200/JCO.22.01482. Epub 2022 Oct 28.
4
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
Breast Cancer Res Treat. 2022 Nov;196(1):153-162. doi: 10.1007/s10549-022-06700-6. Epub 2022 Aug 25.
5
Estimation of the Number of Individuals Living With Metastatic Cancer in the United States.
J Natl Cancer Inst. 2022 Nov 14;114(11):1476-1483. doi: 10.1093/jnci/djac158.
6
Timing evolution of lobular breast cancer through phylogenetic analysis.
EBioMedicine. 2022 Aug;82:104169. doi: 10.1016/j.ebiom.2022.104169. Epub 2022 Jul 23.
7
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
J Clin Oncol. 2022 Mar 20;40(9):978-987. doi: 10.1200/JCO.21.02006. Epub 2022 Jan 7.
8
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Ann Oncol. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19.
9
Diagnosis, biology and epidemiology of oligometastatic breast cancer.
Breast. 2021 Oct;59:144-156. doi: 10.1016/j.breast.2021.06.010. Epub 2021 Jul 1.
10
Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis.
JAMA Surg. 2021 Jun 1;156(6):e210891. doi: 10.1001/jamasurg.2021.0891. Epub 2021 Jun 9.
Zotero 插件